医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CIIE Starts Taking Applications for 2021 Exhibitors

2020年10月17日 AM02:55
このエントリーをはてなブックマークに追加


 

SHANGHAI

Registration for the business exhibition of the fourth China International Import Expo (CIIE) opened on September 28.

The business exhibition of the fourth CIIE welcomes enterprises and organizations registered outside the Chinese mainland. Products produced overseas or services by overseas providers are eligible for the exhibition.

First-time applicants will need to submit their company information at the expo’s website www.ciie.org and wait for review. Participants of this year’s expo can renew their exhibitor status using their existing information.

The fourth CIIE consists of six business exhibition areas — Intelligent Industry and Information Technology Area, Consumer Goods Area, Food and Agricultural Products Area, Medical Equipment and Healthcare Products Area, Automobiles Area, and Trade in Services Area.

The number of Fortune 500 companies and industry leading companies attending the third CIIE is almost identical to that of last year. Many of the world’s top 10 companies in sectors like pharmaceuticals, medical equipment, high-end consumer goods and automobiles have signed up for this year’s expo. In addition, dozens of companies have applied to attend the expo for three consecutive years.

The registration page for the fourth CIIE:

https://www.ciie.org/ciie/f/book/register?locale=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20201016005606/en/

CONTACT

Ms. Nie Qingxin

Tel.:0086-21-67008870/67008988

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™